Free Trial

Carmell (NASDAQ:CTCX) Trading 2.6% Higher - What's Next?

Carmell logo with Medical background

Key Points

  • Carmell Co. (NASDAQ:CTCX) shares increased by 2.6% during mid-day trading, reaching a high of $2.69 before settling at $2.61.
  • A recent Form 13F filing revealed that Citadel Advisors LLC acquired 187,565 shares of Carmell, representing approximately 0.90% of the company.
  • Carmell specializes in bio-aesthetics, utilizing its proprietary Carmell Secretome, which consists of growth factors and proteins extracted from human platelets to support skin and hair health.
  • Five stocks to consider instead of Carmell.

Carmell Co. (NASDAQ:CTCX - Get Free Report)'s stock price traded up 2.6% on Monday . The stock traded as high as $2.69 and last traded at $2.61. 10,534 shares traded hands during trading, a decline of 100% from the average session volume of 4,647,079 shares. The stock had previously closed at $2.54.

Carmell Trading Down 1.6%

The company has a fifty day moving average price of $2.96 and a two-hundred day moving average price of $1.66.

Institutional Investors Weigh In On Carmell

A hedge fund recently bought a new stake in Carmell stock. Citadel Advisors LLC bought a new stake in Carmell Co. (NASDAQ:CTCX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 187,565 shares of the company's stock, valued at approximately $54,000. Citadel Advisors LLC owned about 0.90% of Carmell as of its most recent filing with the SEC. 24.22% of the stock is owned by hedge funds and other institutional investors.

About Carmell

(Get Free Report)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

Featured Articles

Should You Invest $1,000 in Carmell Right Now?

Before you consider Carmell, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carmell wasn't on the list.

While Carmell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.